A new era in the treatment of melanoma: from biology to clinical practice
Clin. transl. oncol. (Print)
; 13(11): 787-792, nov. 2011. ilus
Artigo
em Inglês
| IBECS
| ID: ibc-125938
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Melanoma is the deadliest cutaneous malignancy and its incidence continues to grow. Until 2011, the treatment options for metastatic melanoma were scarce and without any overall survival benefit. The emergence of new targeted therapies for BRAF mutant melanoma (vemurafenib) and immunotherapy (ipilimumab) has changed the standard of care for this disease. The objective of the present review is to summarise the biological background of the new therapeutic approaches in melanoma, focusing on apoptosis resistance, immune modulation and angiogenesis, and the direct translation into clinical practice (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias Cutâneas
/
Proteínas Proto-Oncogênicas B-raf
/
Imunoterapia
/
Melanoma
/
Antineoplásicos
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2011
Tipo de documento:
Artigo
Instituição/País de afiliação:
Clínica Universidad de Navarra/Spain
/
Universidad Complutense/Spain